MedPageToday -- Patients in early-trials of novel cancer treatments overestimate the likelihood that they personally will benefit from the treatment, for reasons that additional pretrial education may not overcome, researchers said. From 26% to 63% of patients in phase I or II cancer therapy trials believed they would fare better than other participants, depending on the specific outcome, according to Lynn A. Jansen, PhD, of Oregon Health and Science University in Portland, and colleagues.